StocksFundsScreenerSectorsWatchlists
IONS

IONS - Ionis Pharmaceuticals Inc Stock Price, Fair Value and News

41.74USD-0.76 (-1.79%)Market Closed

Market Summary

IONS
USD41.74-0.76
Market Closed
-1.79%

IONS Stock Price

View Fullscreen

IONS RSI Chart

IONS Valuation

Market Cap

6.1B

Price/Earnings (Trailing)

-16.61

Price/Sales (Trailing)

7.72

EV/EBITDA

-20.29

Price/Free Cashflow

-18.36

IONS Price/Sales (Trailing)

IONS Profitability

EBT Margin

-42.40%

Return on Equity

-94.72%

Return on Assets

-12.25%

Free Cashflow Yield

-5.45%

IONS Fundamentals

IONS Revenue

Revenue (TTM)

787.6M

Rev. Growth (Yr)

113.65%

Rev. Growth (Qtr)

125.03%

IONS Earnings

Earnings (TTM)

-366.3M

Earnings Growth (Yr)

82.33%

Earnings Growth (Qtr)

93.72%

Breaking Down IONS Revenue

Last 7 days

-3.4%

Last 30 days

-3.3%

Last 90 days

-22.0%

Trailing 12 Months

11.1%

How does IONS drawdown profile look like?

IONS Financial Health

Current Ratio

5.9

Debt/Equity

1.62

Debt/Cashflow

-0.49

IONS Investor Care

Shares Dilution (1Y)

1.96%

Diluted EPS (TTM)

-2.56

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023576.0M630.6M615.0M787.6M
2022840.8M848.8M875.5M587.4M
2021707.5M687.7M660.7M810.5M
2020958.8M940.5M932.7M729.3M
2019752.5M798.5M821.0M1.1B
2018547.3M552.8M579.9M599.7M
2017425.5M499.3M506.7M518.7M
2016258.0M176.0M237.8M346.6M
2015248.6M257.4M274.9M283.7M
2014132.1M151.1M171.5M214.2M
2013122.2M112.9M124.9M147.3M
2012101.2M123.7M114.6M102.0M
201199.7M101.0M93.1M99.1M
2010120.0M112.5M114.3M108.5M
20090112.0M116.8M121.6M
2008000107.2M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Ionis Pharmaceuticals Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 29, 2024
swayze eric
acquired
20,827
34.425
605
officer level 14
Feb 29, 2024
geary richard s
acquired
20,792
34.425
604
officer level 14
Feb 29, 2024
monia brett p
acquired
18,520
34.425
538
ceo level 15
Feb 29, 2024
birchler brian
acquired
20,792
34.425
604
vice president level 14
Feb 29, 2024
bennett c frank
acquired
13,184
34.425
383
officer level 14
Feb 16, 2024
monia brett p
sold
-17,218
44.4924
-387
chief executive officer
Feb 02, 2024
swayze eric
sold
-94,513
49.5613
-1,907
evp research
Feb 02, 2024
cadoret-manier onaiza
sold
-105,404
49.602
-2,125
evp, chf gl pdt str & oper ofc
Feb 02, 2024
o'neil patrick r.
sold
-97,410
49.6738
-1,961
evp clo & general counsel
Feb 02, 2024
schneider eugene
sold
-102,701
49.59
-2,071
evp, chf clinical develop ofcr

1–10 of 50

Which funds bought or sold IONS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 11, 2024
Fortitude Family Office, LLC
sold off
-100
-708
-
-%
Apr 11, 2024
INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC
new
-
334,252
334,252
0.04%
Apr 10, 2024
SOA Wealth Advisors, LLC.
sold off
-100
-2,530
-
-%
Apr 10, 2024
CVA Family Office, LLC
unchanged
-
-217
1,301
-%
Apr 10, 2024
Banque Cantonale Vaudoise
unchanged
-
-3,000
17,000
-%
Apr 09, 2024
MASSMUTUAL TRUST CO FSB/ADV
unchanged
-
-486
2,904
-%
Apr 09, 2024
MATHER GROUP, LLC.
new
-
33,945
33,945
-%
Apr 05, 2024
GAMMA Investing LLC
added
22.4
835
26,530
-%
Apr 05, 2024
CWM, LLC
added
1.41
-14,000
97,000
-%
Apr 03, 2024
Versant Capital Management, Inc
unchanged
-
-427
2,558
-%

1–10 of 39

Are Funds Buying or Selling IONS?

Are funds buying IONS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own IONS
No. of Funds

Unveiling Ionis Pharmaceuticals Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
t. rowe price investment management, inc.
9.2%
13,201,453
SC 13G
Feb 13, 2024
bb biotech ag
6.0%
8,590,000
SC 13G/A
Feb 13, 2024
vanguard group inc
9.90%
14,203,481
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Jan 26, 2024
blackrock inc.
6.3%
9,057,282
SC 13G/A
Jun 09, 2023
vanguard group inc
10.07%
14,414,917
SC 13G/A
Feb 14, 2023
t. rowe price investment management, inc.
8.2%
11,678,259
SC 13G
Feb 14, 2023
bb biotech ag
6.8%
9,635,000
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
9.54%
13,546,694
SC 13G/A

Recent SEC filings of Ionis Pharmaceuticals Inc

View All Filings
Date Filed Form Type Document
Apr 08, 2024
8-K
Current Report
Mar 13, 2024
3
Insider Trading
Mar 13, 2024
4
Insider Trading
Mar 04, 2024
4
Insider Trading
Mar 04, 2024
4
Insider Trading
Mar 04, 2024
4
Insider Trading
Mar 04, 2024
4
Insider Trading
Mar 04, 2024
4
Insider Trading
Feb 29, 2024
8-K
Current Report
Feb 21, 2024
10-K
Annual Report

Peers (Alternatives to Ionis Pharmaceuticals Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
40.2B
6.8B
-1.24% -34.47%
-8.53
5.87
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
18.7B
1.8B
0.05% -28.38%
-42.48
10.23
76.23% 61.08%
17.4B
2.4B
8.82% -6.19%
103.82
7.19
15.42% 18.43%
12.1B
3.7B
-8.57% -28.49%
20.24
3.27
8.87% 75.42%
MID-CAP
6.2B
396.6M
-9.73% -34.59%
-11.81
15.74
425.83% 18.94%
4.7B
-
-4.69% 71.46%
-7.23
60.35
54.84% -34.79%
3.3B
270.6M
-0.99% 6.40%
-13.71
12.12
440.80% -27.84%
3.1B
240.7M
-13.54% -18.95%
-10.32
12.72
-1.03% -92.09%
2.8B
726.4M
-12.42% -7.51%
-46.06
3.89
40.45% 71.62%
SMALL-CAP
1.8B
398.2M
-8.48% -15.36%
25.1
4.5
85.90% -14.05%
599.0M
983.7M
-18.48% -55.04%
-1.1
0.61
-50.36% 17.16%
428.3M
881.7K
-13.30% 407.71%
-9.6
466.16
-77.61% -5.33%
257.8M
4.9M
-1.96% -2.22%
-1.91
52.97
-54.97% 51.72%
7.2M
2.1M
77.59% 88.99%
-0.26
2.14
-13.45% 66.37%

Ionis Pharmaceuticals Inc News

Latest updates
Defense World17 hours ago
San Diego Business Journal6 months ago

Ionis Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue125.0%324,505,000144,207,000188,411,000130,524,000151,889,500159,767,000133,791,000141,919,000440,006,000133,093,000125,750,000111,607,000290,281,000160,079,000145,537,000133,367,000493,680,500167,892,000163,813,000297,214,000192,114,000
Costs and Expenses15.0%330,627,000287,472,000278,606,000244,672,000359,909,000218,921,000219,305,000199,423,000219,403,000218,942,000198,719,000203,578,000312,945,000196,616,000197,291,000194,494,000233,028,000165,369,000182,640,000175,679,000181,331,000
Operating Expenses---------------------181,331,000
  S&GA Expenses1.5%71,010,50069,951,00046,142,00045,516,00047,950,00034,416,00033,802,00034,127,00037,600,00031,093,00056,455,00061,199,000138,866,50068,447,00072,015,00074,994,00083,276,00060,036,00075,111,00068,221,00066,059,000
EBITDA Margin31.6%-0.39-0.58-0.41-0.50-0.400.040.000.02-0.01-0.37-0.28----------
Interest Expenses8.4%4,558,0004,203,0002,291,0001,608,0001,731,0002,139,0002,130,0002,122,0002,238,0002,340,0002,357,0002,414,0002,434,0002,428,0002,441,0002,207,000-22,963,50012,002,00011,802,00011,599,00011,456,500
Income Taxes-1.2%6,518,5006,600,0007,800,00011,380,0008,110,000300,0002,260,0001,094,000334,000-1,300,000300,000130,000341,114,5005,064,0002,084,000-3,072,00042,314,500-14,915,000-6,900,00031,000,000-292,010,500
Earnings Before Taxes98.0%-2,766,500-140,808,000-77,448,000-112,943,000-44,330,000-46,709,000-102,875,000-64,071,000224,914,000-83,773,000-80,548,000-89,739,000-14,572,500-31,550,000-35,476,000-52,954,000230,257,5003,517,000-16,939,000121,931,00010,766,500
EBT Margin30.6%-0.42-0.61-0.45-0.53-0.440.01-0.030.00-0.04-0.41-0.31----------
Net Income93.7%-9,263,000-147,410,000-85,290,000-124,323,000-52,430,000-46,992,000-105,135,000-65,165,000224,613,000-82,466,000-80,875,000-89,869,000-85,987,000-24,467,000-25,636,000-39,628,000184,415,00026,163,000-876,00084,443,000320,078,000
Net Income Margin30.1%-0.47-0.67-0.49-0.57-0.460.01-0.030.00-0.04-0.51-0.46----------
Free Cashflow130.3%33,684,000-111,163,000-109,375,000-144,464,000-204,334,000-29,971,000-21,431,000-34,355,000201,185,000-58,897,000-67,010,000----------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets1.9%2,9902,9342,9712,8852,5342,4222,4562,5192,6122,4152,4972,2492,3903,0963,0793,0913,2332,8952,8782,8362,668
  Current Assets2.2%2,6422,5852,6172,5432,2032,1522,1912,2532,3452,1562,2381,9892,1312,5372,5312,5582,7212,4082,4142,3742,208
    Cash Equivalents13.4%399352425309276315522543869633565414398633530486683248273376279
  Inventory10.9%28.0026.0026.0022.0022.0021.0020.0024.0025.0023.0024.0022.0022.0022.0024.0023.0018.0019.0019.0011.009.00
  Net PPE0.2%71.0071.0092.0085.0074.00181177178178180179180181182173164154149135134132
Liabilities-0.6%2,6032,6192,5432,3991,9611,8281,8311,8101,8401,8841,9141,5681,6461,4891,4841,5211,5491,3971,4211,4481,481
  Current Liabilities10.9%448404288259312283268228241280294295599245231258273232241252280
  Long Term Debt1312.1%62544.00114545-544621543619618617541540450284280435596587577568
    LT Debt, Current-44.00--------62.0062.0062.00309--------
    LT Debt, Non Current1312.1%62544.00114545-544621543619618617541540450284280435596587577568
Shareholder's Equity22.6%3873154284875735946257107725315836817431,5211,5031,4721,5771,4981,4571,3871,101
  Retained Earnings-0.5%-1,795-1,786-1,639-1,553-1,429-1,377-1,330-1,225-1,159-1,384-1,302-1,221-1,131-909-878-846-707-857-883-882-967
  Additional Paid-In Capital3.1%2,2152,1482,1182,0892,0602,0352,0091,9831,9641,9421,9101,9261,8962,3122,2722,2342,2042,2192,1772,1182,047
Shares Outstanding0.7%144143143143142142142142141141141----------
Minority Interest--------------223218210213162188180139
Float---4,243---3,805---4,675---6,748---7,483--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations130.1%32,865-109,022-97,364-133,992-200,195-24,429-18,096-31,650203,687-55,574-62,652-54,66297,977-10,275-44,218-7,592277,839-12,806-27,111107,705115,508
  Share Based Compensation1.4%26,33625,96326,56226,94825,68923,83724,50226,23622,25930,53730,02137,86195,04045,84448,44340,79035,01024,12741,93245,50534,102
Cashflow From Investing-138.9%-26,71368,71169,515-325,640212,147-183,930-3,304-287,54995,109121,971-101,03078,856187,849101,94079,695-95,007138,1911,396-110,687-70,174-326,207
Cashflow From Financing226.2%40,724-32,267143,538492,087-51,0191,8341,215-7,325-62,4901,458314,542-7,577-521,48010,9378,435-94,50119,225-13,17434,51059,4609,646
  Buy Backs---------------48.0090,50034,400----

IONS Income Statement

2023-12-31
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenue:   
Revenue$ 787,647$ 587,367$ 810,456
Expenses:   
Cost of sales9,13314,11610,842
Research, development and patent899,625833,147643,453
Selling, general and administrative232,619150,295186,347
Total operating expenses1,141,377997,558840,642
Loss from operations(353,730)(410,191)(30,186)
Other income (expense):   
Investment income89,04125,33110,044
Interest expense(12,660)(8,122)(9,349)
Interest expense related to sale of future royalties(68,797)00
Gain (loss) on investments(1,914)(7,333)10,103
Gain (loss) on sale of real estate assets(161)149,6040
Other income (expense)14,256(7,274)(9,760)
Loss before income tax benefit (expense)(333,965)(257,985)(29,148)
Income tax benefit (expense)(32,321)(11,737)551
Net loss$ (366,286)$ (269,722)$ (28,597)
Basic net loss per share (in dollars per share)$ (2.56)$ (1.9)$ (0.2)
Shares used in computing basic net loss per share (in shares)143,190141,848141,021
Diluted net loss per share (in dollars per share)$ (2.56)$ (1.9)$ (0.2)
Shares used in computing diluted net loss per share (in shares)143,190141,848141,021
Commercial Revenue [Member]   
Revenue:   
Revenue$ 308,591$ 303,358$ 342,395
SPINRAZA Royalties [Member]   
Revenue:   
Revenue240,379242,314267,776
Other Commercial Revenue [Member]   
Revenue:   
Revenue68,21261,04474,619
Research and Development Revenue [Member]   
Revenue:   
Revenue479,056284,009468,061
Collaborative Agreement Revenue [Member]   
Revenue:   
Revenue352,657207,222468,061
WAINUA Joint Development Revenue [Member]   
Revenue:   
Revenue$ 126,399$ 76,787$ 0

IONS Balance Sheet

2023-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 399,266$ 276,472
Short-term investments1,931,9351,710,397
Contracts receivable97,77825,538
Inventories28,42522,033
Other current assets184,449168,254
Total current assets2,641,8532,202,694
Property, plant and equipment, net71,04374,294
Right-of-use assets171,896181,544
Deposits and other assets105,28075,344
Total assets2,990,0722,533,876
Current liabilities:  
Accounts payable26,02717,921
Accrued compensation67,72749,178
Accrued liabilities147,894140,101
Income taxes payable2,1516,249
0.125 percent convertible senior notes, net44,3320
Current portion of deferred contract revenue151,12890,577
Other current liabilities8,8317,535
Total current liabilities448,090311,561
Long-term deferred contract revenue241,184287,768
Liability related to sale of future royalties, net513,7360
Long-term lease liabilities170,875178,941
Long-term obligations41,83615,973
Total liabilities2,603,3861,960,989
Stockholders' equity:  
Common stock, $0.001 par value; 300,000,000 shares authorized, 144,340,526 and 142,057,736 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively144142
Additional paid-in capital2,215,0982,059,850
Accumulated other comprehensive loss(32,645)(57,480)
Accumulated deficit(1,795,911)(1,429,625)
Total stockholders' equity386,686572,887
Total liabilities and stockholders' equity2,990,0722,533,876
1.75 Percent Convertible Senior Notes [Member]  
Current liabilities:  
Convertible senior notes, net562,2850
0 Percent Convertible Senior Notes [Member]  
Current liabilities:  
Convertible senior notes, net625,380622,242
0.125 Percent Convertible Senior Notes [Member]  
Current liabilities:  
Convertible senior notes, net$ 0$ 544,504
IONS
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops Cimdelirsen to inhibit the production of growth hormone receptor; IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. Ionis Pharmaceuticals, Inc. was incorporated in 1989 and is based in Carlsbad, California.
 CEO
 WEBSITEionispharma.com
 INDUSTRYBiotechnology
 EMPLOYEES796

Ionis Pharmaceuticals Inc Frequently Asked Questions


What is the ticker symbol for Ionis Pharmaceuticals Inc? What does IONS stand for in stocks?

IONS is the stock ticker symbol of Ionis Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ionis Pharmaceuticals Inc (IONS)?

As of Fri Apr 12 2024, market cap of Ionis Pharmaceuticals Inc is 6.08 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IONS stock?

You can check IONS's fair value in chart for subscribers.

What is the fair value of IONS stock?

You can check IONS's fair value in chart for subscribers. The fair value of Ionis Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Ionis Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for IONS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Ionis Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether IONS is over valued or under valued. Whether Ionis Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Ionis Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IONS.

What is Ionis Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 12 2024, IONS's PE ratio (Price to Earnings) is -16.61 and Price to Sales (PS) ratio is 7.72. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IONS PE ratio will change depending on the future growth rate expectations of investors.